NO306257B1 - 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav - Google Patents

11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav

Info

Publication number
NO306257B1
NO306257B1 NO963427A NO963427A NO306257B1 NO 306257 B1 NO306257 B1 NO 306257B1 NO 963427 A NO963427 A NO 963427A NO 963427 A NO963427 A NO 963427A NO 306257 B1 NO306257 B1 NO 306257B1
Authority
NO
Norway
Prior art keywords
ostra
pharmaceutical composition
substituted phenyl
diene derivatives
diene
Prior art date
Application number
NO963427A
Other languages
English (en)
Norwegian (no)
Other versions
NO963427D0 (no
NO963427L (no
Inventor
Ronald Gebhard
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306257(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO963427D0 publication Critical patent/NO963427D0/no
Publication of NO963427L publication Critical patent/NO963427L/no
Publication of NO306257B1 publication Critical patent/NO306257B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO963427A 1995-08-17 1996-08-16 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav NO306257B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202229 1995-08-17

Publications (3)

Publication Number Publication Date
NO963427D0 NO963427D0 (no) 1996-08-16
NO963427L NO963427L (no) 1997-02-18
NO306257B1 true NO306257B1 (no) 1999-10-11

Family

ID=8220570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963427A NO306257B1 (no) 1995-08-17 1996-08-16 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav

Country Status (25)

Country Link
US (1) US6011025A (fr)
EP (1) EP0763541B1 (fr)
JP (1) JP3977462B2 (fr)
KR (1) KR100445376B1 (fr)
CN (1) CN1129602C (fr)
AR (1) AR003982A1 (fr)
AT (1) ATE182596T1 (fr)
AU (1) AU711369B2 (fr)
BR (1) BR9603429A (fr)
CA (1) CA2182771C (fr)
CZ (1) CZ287740B6 (fr)
DE (1) DE69603425T2 (fr)
DK (1) DK0763541T3 (fr)
ES (1) ES2137625T3 (fr)
GR (1) GR3031116T3 (fr)
HU (1) HU229023B1 (fr)
IL (1) IL118974A (fr)
NO (1) NO306257B1 (fr)
NZ (1) NZ299181A (fr)
PL (1) PL183468B1 (fr)
RU (1) RU2135514C1 (fr)
SG (1) SG52834A1 (fr)
TR (1) TR199600664A2 (fr)
TW (1) TW464654B (fr)
ZA (1) ZA966555B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (fr) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
CN1187053C (zh) * 1997-10-06 2005-02-02 利兰·斯坦福青年大学托管委员会 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
EP1726307A3 (fr) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methodes de traitement de la psychose associee a un dysfonctionnement lie aux glucocorticoides
IL139672A (en) 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia
US6756366B1 (en) * 1999-04-06 2004-06-29 Akzo Nobel N.V. Orally active androgens
WO2002064550A1 (fr) * 2001-02-14 2002-08-22 Abbott Laboratories Modulateurs des recepteurs des glucocorticoides
EP1285927A3 (fr) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Utilisation d'antagonistes du récepteur glucocorticoide pour la prévention et traitement des maladies de la fonction reproductive masculine
PT1652526E (pt) * 2001-10-26 2009-02-06 Organon Nv Utilização de (11β,17β)-11-(1,3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)-estra-4,9-dien-3-ona no tratamento de desordem depressiva grave
AU2002366217A1 (en) 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
EP1581234A4 (fr) * 2002-11-05 2007-09-12 Corcept Therapeutics Inc Procédés pour traiter la migraine
US20040229855A1 (en) * 2003-02-04 2004-11-18 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
EP2671086B1 (fr) * 2011-02-03 2018-04-25 Pop Test Oncology LLC Système et méthode de diagnostic et de traitement
WO2012129305A1 (fr) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Polythérapie
US8865693B2 (en) 2011-03-31 2014-10-21 Pop Test Cortisol Llc Prevention of infection
EP2699245A4 (fr) * 2011-04-18 2014-12-10 Pop Test Cortisol Llc Traitement contre la perte des cheveux
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
US9662392B2 (en) 2014-06-03 2017-05-30 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
WO2016140867A1 (fr) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Utilisation d'un antagoniste du récepteur des glucocorticoïdes et d'analogues de la somatostatine pour le traitement de tumeurs secrétant de l'hormone adrénocorticotrope (acth)
WO2016154203A1 (fr) * 2015-03-23 2016-09-29 Evestra, Inc. Nouveaux agents cytotoxiques qui ciblent préférentiellement le facteur d'inhibition de la leucémie (lif) pour le traitement de tumeurs malignes et comme nouveaux agents contraceptifs
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3400233B1 (fr) * 2015-08-03 2025-10-22 Pop Test Oncology LLC Compositions pharmaceutiques et méthodes
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (fr) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibiteurs de récepteurs glucocorticoïdes
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
PL3523315T3 (pl) * 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE59010853D1 (de) * 1989-08-04 1998-12-03 Schering Ag 11 Beta-Aryl-gona-4,9-dien-3-one
EP0712311B1 (fr) * 1993-08-04 1998-10-07 Akzo Nobel N.V. Steroides antiglucocorticoides destines au traitement de troubles associes a l'anxiete
ATE156836T1 (de) * 1994-05-19 1997-08-15 Akzo Nobel Nv 11,21-bisphenyl-19-nor-pregnan derivate

Also Published As

Publication number Publication date
AU711369B2 (en) 1999-10-14
CZ287740B6 (en) 2001-01-17
KR970010784A (ko) 1997-03-27
GR3031116T3 (en) 1999-12-31
EP0763541A1 (fr) 1997-03-19
DK0763541T3 (da) 2000-02-28
KR100445376B1 (ko) 2004-11-08
ES2137625T3 (es) 1999-12-16
MX9603476A (es) 1997-07-31
JP3977462B2 (ja) 2007-09-19
HUP9602269A2 (en) 1997-04-28
CZ238696A3 (en) 1997-05-14
ZA966555B (en) 1997-02-19
HU229023B1 (en) 2013-07-29
DE69603425T2 (de) 2000-01-20
CA2182771A1 (fr) 1997-02-18
HK1002010A1 (en) 1998-07-24
CA2182771C (fr) 2007-04-24
NO963427D0 (no) 1996-08-16
US6011025A (en) 2000-01-04
RU2135514C1 (ru) 1999-08-27
ATE182596T1 (de) 1999-08-15
EP0763541B1 (fr) 1999-07-28
DE69603425D1 (de) 1999-09-02
AU6211996A (en) 1997-02-20
BR9603429A (pt) 1998-05-12
TW464654B (en) 2001-11-21
JPH09104696A (ja) 1997-04-22
PL183468B1 (pl) 2002-06-28
IL118974A0 (en) 1996-10-31
CN1129602C (zh) 2003-12-03
SG52834A1 (en) 1998-09-28
IL118974A (en) 2001-09-13
PL315733A1 (en) 1997-03-03
CN1147520A (zh) 1997-04-16
NZ299181A (en) 1997-09-22
TR199600664A2 (tr) 1997-03-21
HU9602269D0 (en) 1996-10-28
NO963427L (no) 1997-02-18
AR003982A1 (es) 1998-09-30
HUP9602269A3 (en) 1997-12-29

Similar Documents

Publication Publication Date Title
NO973612D0 (no) Nytt farmasöytisk preparat
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
DE69513671D1 (de) Arzneimittel
ATE367150T1 (de) Arzneimittel
NO20021172D0 (no) Farmasöytisk sammensetning
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
DK0763541T3 (da) 11-(substitueret phenyl)-estra-4,9-dien-derivater
NO996372D0 (no) Fast farmasoeytisk preparat inneholdende benzofuanderivater
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
NO20011157D0 (no) Benzenderivater og farmasøytisk anvendelse derav
NO963032D0 (no) Oralt preparat
NO20005399L (no) Farmasöytisk preparat
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
NO973610D0 (no) Nytt farmasöytisk preparat
LV11727A (lv) Farmaceitiska kompozicija
EE9800209A (et) Antiglükokortikoidne ravimaine
ID18698A (id) Komposisi farmasi
FI973280A0 (fi) Farmaseuttinen koostumus
NO973611D0 (no) Nytt farmasöytisk preparat
NO950950D0 (no) Farmasöytisk preparat
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
FI961364L (fi) Lääkeainekoostumus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees